Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
South Korea will expand the use of AstraZeneca's COVID-19 vaccine to people aged 65 and older to ramp up the vaccine rollout as new overseas studies showed its effectiveness, health authorities said Thursday.
The Korea Disease Control and Prevention Agency (KDCA) initially excluded administering vaccines developed by British-Swedish pharmaceutical giant AstraZeneca and Oxford University to the elderly, citing insufficient clinical data.
The inoculation campaign -- launched in late February -- will now allow using AstraZeneca products on all adults aged 18 and over, including health care workers and patients at long-term care facilities who are among the first in line, the KDCA said.
An independent panel under the health ministry earlier recommended that the AstraZeneca vaccine be approved for older people, following in the footsteps of several European countries that reversed decisions on the two-dose regimen.
The panel's decision to lift the age limit was based on data released in England and Scotland, revealing its effectiveness in preventing infection and lowering hospitalizations among elderly people.
British health authorities announced that vaccines are more than 70 percent effective in preventing infection from the COVID-19 virus in those over 80 after one dose of the shot.
Another study from Scotland showed that AstraZeneca vaccines showed a maximum 94 percent effectiveness in preventing hospitalizations in those aged over 80.
The authorities also said an inter-dose interval will be extended from the current eight to 12 weeks for AstraZeneca products.
The approval could speed up the country's inoculation campaign, which includes administering AstraZeneca products to 376,000 health care workers and patients aged 65 and older at sanatoriums, nursing facilities and rehabilitation facilities within this month.
The authorities also announced that a second batch of AstraZeneca's COVID-19 vaccines for around 3.5 million people will arrive in the country between late May and early June.
The second shipment of 7 million doses of vaccines is part of the deal for 10 million people, it said. The first batch for 785,000 people already arrived here last month and was administered.
The government has already secured enough COVID-19 vaccines to inoculate 79 million people under the World Health Organization's global vaccine COVAX Facility project and separate contracts with five foreign drug firms, more than South Korea's population of 52 million.
The KDCA said it will announce details on the inoculation schedule for the second quarter on Monday. (Yonhap)
The Korea Disease Control and Prevention Agency (KDCA) initially excluded administering vaccines developed by British-Swedish pharmaceutical giant AstraZeneca and Oxford University to the elderly, citing insufficient clinical data.
The inoculation campaign -- launched in late February -- will now allow using AstraZeneca products on all adults aged 18 and over, including health care workers and patients at long-term care facilities who are among the first in line, the KDCA said.
An independent panel under the health ministry earlier recommended that the AstraZeneca vaccine be approved for older people, following in the footsteps of several European countries that reversed decisions on the two-dose regimen.
The panel's decision to lift the age limit was based on data released in England and Scotland, revealing its effectiveness in preventing infection and lowering hospitalizations among elderly people.
British health authorities announced that vaccines are more than 70 percent effective in preventing infection from the COVID-19 virus in those over 80 after one dose of the shot.
Another study from Scotland showed that AstraZeneca vaccines showed a maximum 94 percent effectiveness in preventing hospitalizations in those aged over 80.
The authorities also said an inter-dose interval will be extended from the current eight to 12 weeks for AstraZeneca products.
The approval could speed up the country's inoculation campaign, which includes administering AstraZeneca products to 376,000 health care workers and patients aged 65 and older at sanatoriums, nursing facilities and rehabilitation facilities within this month.
The authorities also announced that a second batch of AstraZeneca's COVID-19 vaccines for around 3.5 million people will arrive in the country between late May and early June.
The second shipment of 7 million doses of vaccines is part of the deal for 10 million people, it said. The first batch for 785,000 people already arrived here last month and was administered.
The government has already secured enough COVID-19 vaccines to inoculate 79 million people under the World Health Organization's global vaccine COVAX Facility project and separate contracts with five foreign drug firms, more than South Korea's population of 52 million.
The KDCA said it will announce details on the inoculation schedule for the second quarter on Monday. (Yonhap)
